Halozyme Beats Estimates with 48% Revenue Surge, Raises Full-Year Guidance — Halozyme Therapeutics, Inc.

Event summary

Halozyme reported Q2 2026 revenue of $481 million, up 48% YoY, driven by a 50% increase in royalty revenue to $308 million.
The company raised its full-year 2026 guidance, projecting total revenue of $1.835 billion to $1.910 billion, representing growth of 31% to 37%.
Halozyme signed five new ENHANZE® and Hypercon™ collaboration agreements in the first seven months of 2026, exceeding its annual goal.
The company repurchased $333 million of shares in Q2 2026 at an average price of $69.30 per share.

The big picture

Halozyme's strong Q2 performance underscores the scalability and durability of its ENHANZE® platform, attracting high-profile partners like Vertex and GSK. The company's ability to raise guidance reflects confidence in its pipeline and strategic acquisitions. As biotech firms increasingly seek innovative drug delivery solutions, Halozyme's technology portfolio positions it as a key player in reducing treatment burden for patients.

What we're watching

Revenue Diversification: Whether Halozyme can sustain its revenue growth through continued partnerships and product launches.
Execution Risk: The pace at which Halozyme can integrate and commercialize its recent acquisitions, Elektrofi and Surf Bio.
Market Dynamics: How the competitive landscape in drug delivery technology will impact Halozyme's long-term positioning.